Compare NVAX & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | REAL |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 1996 | 2019 |
| Metric | NVAX | REAL |
|---|---|---|
| Price | $9.58 | $8.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $11.33 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 4.4M | 3.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | 43.55 |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $1,123,479,000.00 | $692,845,000.00 |
| Revenue This Year | N/A | $14.30 |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | $3.77 | ★ N/A |
| Revenue Growth | ★ 64.69 | 15.38 |
| 52 Week Low | $5.01 | $4.61 |
| 52 Week High | $11.85 | $17.39 |
| Indicator | NVAX | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 25.48 |
| Support Level | $9.14 | $7.21 |
| Resistance Level | $10.42 | $11.48 |
| Average True Range (ATR) | 0.60 | 0.60 |
| MACD | -0.13 | -0.11 |
| Stochastic Oscillator | 16.52 | 0.26 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.